CATO SMS Appoints Regulatory Strategy Leader in Pharmacology and Toxicology
DECEMBER 8, 2021 CARY, N.C., December 8, 2021– CATO SMS, a global provider of specialized clinical research solutions, announced today that it has appointed Marcus S. Delatte, Ph.D. as vice president of nonclinical regulatory strategy. Dr. Delatte brings to CATO SMS more than 10 years of experience as a senior pharmacology/toxicology reviewer and regulatory scientist with […]
CATO SMS Appoints Vice President of Regulatory Strategy Cell and Gene Therapy
SEPTEMBER 30, 2021 CARY, N.C., September 30, 2021– CATO SMS, a global provider of specialized clinical research solutions, announced today the appointment of Jessica Lee, M.D., Ph.D., as vice president, Regulatory Strategy, Cell and Gene Therapy. A board-certified oncologist and regulatory expert, Dr. Lee brings to CATO SMS nearly 20 years of clinical practice and health authority […]
CATO SMS Appoints Dr. Teresa Nunes Chief Medical Officer
SEPTEMBER 13, 2021 Pharmaceutical Physician to Spearhead Global Provider’s Growing Medical Services & Pharmacovigilance Groups CARY, N.C., September 13, 2021 – CATO SMS, a global provider of specialized clinical research solutions, announced today the appointment of Teresa Nunes, M.D. as chief medical officer. Dr. Nunes will lead the company’s fast-growing medical services and pharmacovigilance groups. She also […]
CATO SMS Appoints Vice President of Regulatory Strategy
SEPTEMBER 2, 2021 CARY, N.C., September 2, 2021 – CATO SMS, a global provider of specialized clinical research solutions, announced today that it has appointed Richard Vesely, M.D. as vice president of regulatory strategy. He brings to CATO SMS nearly 30 years of European regulatory and clinical experience in a range of therapeutic areas, including immunology, rheumatology, […]
CATO SMS Appoints President of Clinical Trial Operations
JULY 7, 2021 CARY, N.C., July 7, 2021 – CATO SMS, a global provider of specialized clinical research solutions, announced today that it has appointed Robert Millham to president of clinical trial operations. A highly accomplished drug development executive, Mr. Millham joins CATO SMS as the company continues its expansion to broaden and deepen its offering to […]
CATO SMS Appoints Regulatory Strategy Leader
JUNE 9, 2021 CARY, N.C., June 9, 2021 – CATO SMS,a global provider of specialized clinical research solutions, announced today that it has appointed Dr. Ernesto Vera-Sanchez to vice president of regulatory strategy and head of Good Practices (GxP) consulting services. Dr. Vera-Sanchez, who brings to CATO SMS nearly 20 years of global regulator and inspectorate […]
CATO SMS Acquires Nuventra To Expand Drug Development Offering Into Clinical Pharmacology
MAY 26, 2021 CARY, N.C., May 26, 2021 – CATO SMS,a global provider of regulatory and clinical research services, announced today that it has acquired Nuventra, Inc. to extend its offering into the critical area of clinical pharmacology. Headquartered in Durham, N.C., Nuventra is one of the industry’s leading clinical pharmacology science and services providers. The acquisition expands CATO SMS’ […]
Pharm-Olam Enrolling UK Volunteers for Phase 3 Valneva COVID-19 Vaccine Study
Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions is now enrolling volunteers in the United Kingdom into a pivotal Phase III COVID-19 vaccine study. MAY 20, 2021 HOUSTON, Texas, May 10, 2021 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for infectious diseases, vaccines, rare and orphan diseases along with oncology, […]
CATO SMS Announces Consulting Leadership Appointment
MARCH 3, 2021 Global Provider Appoints Leslie DeVos to Spearhead Continued Expansion of Consulting Capabilities CARY, N.C., March 3, 2021 – CATO SMS,a global provider of regulatory and clinical research services, announced today that it has appointed Leslie DeVos to president of its consulting business. Ms. DeVos will spearhead the company’s continued expansion of its consulting […]
US Department of Defense selects Pharm-Olam as CRO for Adalimumab COVID Therapeutic Trial
Pharm-Olam has been selected by the U.S. Department of Defense to lead and provide full service clinical trial support of the Adalimumab COVID Therapeutic Trial. JANUARY 19, 2021 HOUSTON, Texas, January 4, 2021 – Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense’s (DOD) Joint Program Executive […]